By JP Ellison –
In a speech on January 29th at the CBI Pharmaceutical Compliance Congress that DOJ posted on its own website, U.S. Department of Justice Assistant Attorney General Stuart Delery set forth his views of the three ways that the government’s enforcement interests align with industry’s interests. While the speech didn’t break any new ground, it serves as a reminder that pharmaceutical enforcement cases remain a DOJ priority and suggests that recent enforcement trends will continue.
AAG Delery Claimed that DOJ and industry shared the following:
In a speech on January 29th at the CBI Pharmaceutical Compliance Congress that DOJ posted on its own website, U.S. Department of Justice Assistant Attorney General Stuart Delery set forth his views of the three ways that the government’s enforcement interests align with industry’s interests. While the speech didn’t break any new ground, it serves as a reminder that pharmaceutical enforcement cases remain a DOJ priority and suggests that recent enforcement trends will continue.
AAG Delery Claimed that DOJ and industry shared the following:
- “[A] common interest in promoting ethical corporate culture instead of maintaining a compliance program in name only;”
- “Transparency about the conduct [the government] investigate[s];” and
- “[A] common interest in ensuring that corporate compliance is not only the right thing to do but also a winning business strategy.”
No comments:
Post a Comment